Enhanced Agglutination Reaction of ABO Subgroups by Gold Nanoparticle Solution: Implication for Identification of ABO Subgroups

$113.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Although the ABO blood group is the most significant in blood group system in human, other subgroups system is also important to be concerned in blood banking laboratory. ABO subgroups have weak antigen potency on red blood cell. In some cases, they could not been detected by cell grouping and serum grouping methods. This may lead to misinterpretation of ABO typing which will cause serious problems for transfusion and transplantation. Gold nanoparticle solution can increase the agglutination reaction of ABO typing. Thus far, the investigation of ABO blood group system has been performed using gold nanoparticle solution. Samples were tested comparing between with and without gold nanoparticle solution. After reading the agglutination reaction, supernatants were collected and measured at the optical density at 760 nm by spectrophotometer. The optical density of 2–5% cell suspension and monoclonal antibody was higher than in the tube of 2–5% cell suspension, monoclonal antibody and gold nanoparticle solution. By adding the gold nanoparticle solution, the agglutination reaction was increased ranging from 7.0–37.7% (median 15.0%) for ABO grouping system whereas 12.1–50.9% (median 23.4%) was observed in ABO subgroups. It could decrease the chance of misinterpretation by 33.3%. By using gold nanoparticle solution might be the alternative way for investigation of weak antigen potency on red blood cell.

Keywords: ABO DISCREPANCIES; ABO SUBGROUPS; GOLD NANOPARTICLE SOLUTION

Document Type: Research Article

DOI: http://dx.doi.org/10.1166/jbn.2011.1351

Publication date: December 1, 2011

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • ingentaconnect is not responsible for the content or availability of external websites
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more